Polyphenols in Prostate Cancer

Polyphenols in Human Health and Disease

Volumn 2, Issue , 2013, Pages 1217-1230

  Brizuela, Leyre ^a,b   Cuvillier, Olivier ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Chemoprevention; Epigallocatechin 3 gallate; Green tea; Polyphenols; Prostate cancer; Resveratrol

Indexed keywords

EID: 84902555736     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-398456-2.00092-X     Document Type: Chapter

References (126)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60(5):277-300.
2. Sturge J., Caley M.P., Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8(6):357-368.
3. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11(6):411-425.
4. Syed D.N., Khan N., Afaq F., Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007, 16(11):2193-2203.
5. Khan N., Adhami V.M., Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 2010, 17(1):R39-52.
6. Ozten-Kandas N., Bosland M.C. Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants - In vivo evidence. J Carcinog 2011, 10:27.
7. Van Poppel H., Tombal B. Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res 2011, 3:91-100.
8. Thapa D., Ghosh R. Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol 2012, 83(10):1319-1330.
9. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24(5A):2783-2840.
10. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275(5297):218-220.
11. Hung L.M., Chen J.K., Huang S.S., Lee R.S., Su M.J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000, 47(3):549-555.
12. Chen C.K., Pace-Asciak C.R. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996, 27(2):363-366.
13. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995, 235(2):207-219.
14. Von Low E.C., Perabo F.G., Siener R., Muller S.C. Review. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo 2007, 21(2):189-204.
15. Athar M., Back J.H., Kopelovich L., Bickers D.R., Kim A.L. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009, 486(2):95-102.
16. Gupta S.C., Kannappan R., Reuter S., Kim J.H., Aggarwal B.B. Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 2011, 1215:150-160.
17. Dhar S., Hicks C., Levenson A.S. Resveratrol and prostate cancer: promising role for microRNAs. Mol Nutr Food Res 2011, 55(8):1219-1229.
18. Aziz M.H., Kumar R., Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 2003, 23(1):17-28.
19. Stewart J.R., Artime M.C., O'Brian C.A. Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr 2003, 133(7 Suppl):2440S-2443S.
20. Hsieh T.C., Wu J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 1999, 249(1):109-115.
21. Hsieh T.C., Wu J.M. Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 2000, 20(1A):225-228.
22. Mitchell S.H., Zhu W., Young C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 1999, 59(23):5892-5895.
23. Sgambato A., Ardito R., Faraglia B., Boninsegna A., Wolf F.I., Cittadini A. Resveratrol a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 2001, 496(1-2):171-180.
24. Kuwajerwala N., Cifuentes E., Gautam S., Menon M., Barrack E.R., Reddy G.P. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 2002, 62(9):2488-2492.
25. Lin H.Y., Shih A., Davis F.B., Tang H.Y., Martino L.J., Bennett J.A., et al. Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 2002, 168(2):748-755.
26. Morris G.Z., Williams R.L., Elliott M.S., Beebe S.J. Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells. Prostate 2002, 52(4):319-329.
27. Narayanan B.A., Narayanan N.K., Re G.G., Nixon D.W. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 2003, 104(2):204-212.
28. Stewart J.R., O'Brian C.A. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 2004, 22(2):107-117.
29. Kampa M., Hatzoglou A., Notas G., Damianaki A., Bakogeorgou E., Gemetzi C., et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 2000, 37(2):223-233.
30. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004, 64(1):337-346.
31. Kim Y.A., Rhee S.H., Park K.Y., Choi Y.H. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 2003, 6(4):273-280.
32. Cardile V., Scifo C., Russo A., Falsaperla M., Morgia G., Motta M., et al. Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer. Anticancer Res 2003, 23(6C):4921-4926.
33. Gao S., Liu G.Z., Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 2004, 59(2):214-225.
34. Kotha A., Sekharam M., Cilenti L., Siddiquee K., Khaled A., Zervos A.S., et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 2006, 5(3):621-629.
35. Aziz M.H., Nihal M., Fu V.X., Jarrard D.F., Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 2006, 5(5):1335-1341.
36. Benitez D.A., Pozo-Guisado E., Alvarez-Barrientos A., Fernandez-Salguero P.M., Castellon E.A. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007, 28(2):282-293.
37. Shankar S., Siddiqui I., Srivastava R.K. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 2007, 304(1-2):273-285.
38. Benitez D.A., Hermoso M.A., Pozo-Guisado E., Fernandez-Salguero P.M., Castellon E.A. Regulation of cell survival by resveratrol involves inhibition of NFκB-regulated gene expression in prostate cancer cells. Prostate 2009, 69(10):1045-1054.
39. Kai L., Samuel S.K., Levenson A.S. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 2010, 126(7):1538-1548.
40. Slusarz A., Shenouda N.S., Sakla M.S., Drenkhahn S.K., Narula A.S., MacDonald R.S., et al. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res 2010, 70(8):3382-3390.
41. Brizuela L., Dayon A., Doumerc N., Ader I., Golzio M., Izard J.C., et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J 2010, 24(10):3882. 94.
42. Wang Y., Romigh T., He X., Orloff M.S., Silverman R.H., Heston W.D., et al. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet 2010, 19(22):4319-4329.
43. Hsieh T.C., Huang Y.C., Wu J.M. Control of prostate cell growth, DNA damage and repair and gene expression by resveratrol analogues, in vitro. Carcinogenesis 2011, 32(1):93-101.
44. Rashid A., Liu C., Sanli T., Tsiani E., Singh G., Bristow R.G., et al. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol 2011, 6:144.
45. Fang Y., DeMarco V.G., Nicholl M.B. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci 2012, 103(6):1090-1098.
46. Sheth S., Jajoo S., Kaur T., Mukherjea D., Sheehan K., Rybak L.P., et al. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One 2012, 7(12):e51655.
47. Li G., Rivas P., Bedolla R., Thapa D., Reddick R.L., Ghosh R., et al. Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res (Phila) 2013, 6(1):27-39.
48. Harper C.E., Patel B.B., Wang J., Arabshahi A., Eltoum I.A., Lamartiniere C.A. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007, 28(9):1946-1953.
49. Seeni A., Takahashi S., Takeshita K., Tang M., Sugiura S., Sato S.Y., et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008, 9(1):7-14.
50. Wang T.T., Hudson T.S., Wang T.C., Remsberg C.M., Davies N.M., Takahashi Y., et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008, 29(10):2001-2010.
51. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009, 125(1):1-8.
52. Ganapathy S., Chen Q., Singh K.P., Shankar S., Srivastava R.K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 2010, 5(12):e15627.
53. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003, 4(5):397-407.
54. Maceyka M., Harikumar K.B., Milstien S., Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012, 22(1):50-60.
55. Malavaud B., Pchejetski D., Mazerolles C., de Paiva G.R., Calvet C., Doumerc N., et al. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer 2010, 46(18):3417-3424.
56. Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta 2002, 1585(2-3):153-162.
57. Cuvillier O., Levade T. Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacol Res 2003, 47(5):439-445.
58. Cuvillier O., Ader I., Bouquerel P., Brizuela L., Gstalder C., Malavaud B. Hypoxia, therapeutic resistance, and sphingosine 1-phosphate. Adv Cancer Res 2013, 117:117-141.
59. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325(5945):1254-1257.
60. Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M., Kim E.Y., et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010, 465(7301):1084-1088.
61. Strub G.M., Paillard M., Liang J., Gomez L., Allegood J.C., Hait N.C., et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J 2011, 25(2):600-612.
62. Chun J., Hla T., Lynch K.R., Spiegel S., Moolenaar W.H. International union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 2010, 62(4):579-587.
63. Scarlatti F., Sala G., Ricci C., Maioli C., Milani F., Minella M., et al. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 2007, 253(1):124-130.
64. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003, 36(1):79-87.
65. Wang Z., Zou J., Huang Y., Cao K., Xu Y., Wu J.M. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 2002, 115(3):378-380.
66. Blardi P., De Lalla A., Volpi L., Di Perri T. Stimulation of endogenous adenosine release by oral administration of quercetin and resveratrol in man. Drugs Exp Clin Res 1999, 25(2-3):105-110.
67. Hara Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol Res 2011, 64(2):100-104.
68. Lambert J.D., Hong J., Yang G.Y., Liao J., Yang C.S. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005, 81(1 Suppl):284S-291S.
69. Doss M.X., Potta S.P., Hescheler J., Sachinidis A. Trapping of growth factors by catechins: a possible therapeutical target for prevention of proliferative diseases. J Nutr Biochem 2005, 16(5):259-266.
70. Siddiqui I.A., Adhami V.M., Saleem M., Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol Nutr Food Res 2006, 50(2):130-143.
71. Pandey M., Gupta S. Green tea and prostate cancer: from bench to clinic. Front Biosci (Elite Ed) 2009, 1:13-25.
72. Liao S., Hiipakka R.A. Selective inhibition of steroid 5 α-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995, 214(3):833-838.
73. Ahmad N., Feyes D.K., Nieminen A.L., Agarwal R., Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997, 89(24):1881-1886.
74. Paschka A.G., Butler R., Young C.Y. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett 1998, 130(1-2):1-7.
75. Gupta S., Ahmad N., Mohan R.R., Husain M.M., Mukhtar H. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999, 59(9):2115-2120.
76. Gupta S., Ahmad N., Nieminen A.L., Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000, 164(1):82-90.
77. Ren F., Zhang S., Mitchell S.H., Butler R., Young C.Y. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000, 19(15):1924-1932.
78. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000, 60(8):1051-1059.
79. Kazi A., Smith D.M., Zhong Q., Dou Q.P. Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis. Mol Pharmacol 2002, 62(4):765-771.
80. Gupta S., Hussain T., Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003, 410(1):177-185.
81. Hastak K., Gupta S., Ahmad N., Agarwal M.K., Agarwal M.L., Mukhtar H. Role of p53 and NFκB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003, 22(31):4851-4859.
82. Brusselmans K., De Schrijver E., Heyns W., Verhoeven G., Swinnen J.V. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 2003, 106(6):856-862.
83. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003, 63(22):7563-7570.
84. Siddiqui I.A., Adhami V.M., Afaq F., Ahmad N., Mukhtar H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 2004, 91(2):232-242.
85. Caporali A., Davalli P., Astancolle S., D'Arca D., Brausi M., Bettuzzi S., et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004, 25(11):2217-2224.
86. Pezzato E., Sartor L., Dell'Aica I., Dittadi R., Gion M., Belluco C., et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 2004, 112(5):787-792.
87. Hussain T., Gupta S., Adhami V.M., Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005, 113(4):660-669.
88. Hastak K., Agarwal M.K., Mukhtar H., Agarwal M.L. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005, 19(7):789-791.
89. Adhami V.M., Malik A., Zaman N., Sarfaraz S., Siddiqui I.A., Syed D.N., et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007, 13(5):1611-1619.
90. Albrecht D.S., Clubbs E.A., Ferruzzi M., Bomser J.A. Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem Biol Interact 2008, 171(1):89-95.
91. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008, 27(14):2055-2063.
92. Thomas F., Patel S., Holly J.M., Persad R., Bahl A., Perks C.M. Dihydrotestosterone sensitises LNCaP cells to death induced by epigallocatechin-3-gallate (EGCG) or an IGF-I receptor inhibitor. Prostate 2009, 69(2):219-224.
93. Pandey M., Shukla S., Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer 2010, 126(11):2520-2533.
94. Duhon D., Bigelow R.L., Coleman D.T., Steffan J.J., Yu C., Langston W., et al. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog 2010, 49(8):739-749.
95. Siddiqui I.A., Asim M., Hafeez B.B., Adhami V.M., Tarapore R.S., Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011, 25(4):1198-1207.
96. Davalli P., Rizzi F., Caldara G.F., Davoli S., Corti A., Silva A., et al. Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterations of protein post-translational processing. Int J Oncol 2011, 39(6):1521-1527.
97. Thakur V.S., Gupta K., Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis 2012, 33(2):377-384.
98. Lee Y.H., Kwak J., Choi H.K., Choi K.C., Kim S., Lee J., et al. EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. Int J Mol Med 2012, 30(1):69-74.
99. Thakur V.S., Gupta K., Gupta S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol 2012, 41(1):353-361.
100. Liao S., Umekita Y., Guo J., Kokontis J.M., Hiipakka R.A. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995, 96(2):239-243.
101. Gupta S., Hastak K., Ahmad N., Lewin J.S., Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001, 98(18):10350-10355.
102. Adhami V.M., Siddiqui I.A., Ahmad N., Gupta S., Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004, 64(23):8715-8722.
103. Saleem M., Adhami V.M., Ahmad N., Gupta S., Mukhtar H. Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res 2005, 11(1):147-153.
104. Roomi M.W., Ivanov V., Kalinovsky T., Niedzwiecki A., Rath M. In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo 2005, 19(1):179-183.
105. Siddiqui I.A., Zaman N., Aziz M.H., Reagan-Shaw S.R., Sarfaraz S., Adhami V.M., et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 2006, 27(4):833-839.
106. Harper C.E., Patel B.B., Wang J., Eltoum I.A., Lamartiniere C.A. Epigallocatechin-3-gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 2007, 67(14):1576-1589.
107. Siddiqui I.A., Shukla Y., Adhami V.M., Sarfaraz S., Asim M., Hafeez B.B., et al. Suppression of NFκB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm Res 2008, 25(9):2135-2142.
108. McCarthy S., Caporali A., Enkemann S., Scaltriti M., Eschrich S., Davalli P., et al. Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol 2007, 1(2):196-204.
109. Lee S.C., Chan W.K., Lee T.W., Lam W.H., Wang X., Chan T.H., et al. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Nutr Cancer 2008, 60(4):483-491.
110. O'Sullivan J., Sheridan J., Mulcahy H., Tenniswood M., Morrissey C. The effect of green tea on oxidative damage and tumour formation in Lobund-Wistar rats. Eur J Cancer Prev 2008, 17(6):489-501.
111. Adhami V.M., Siddiqui I.A., Sarfaraz S., Khwaja S.I., Hafeez B.B., Ahmad N., et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009, 15(6):1947-1953.
112. Henning S.M., Wang P., Said J., Magyar C., Castor B., Doan N., et al. Polyphenols in brewed green tea inhibit prostate tumor xenograft growth by localizing to the tumor and decreasing oxidative stress and angiogenesis. J Nutr Biochem 2012, 23(11):1537-1542.
113. Kim M.H., Chung J. Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line. Anticancer Res 2007, 27(6B):3947-3956.
114. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E., Mack T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991, 63(6):963-966.
115. Haenszel W., Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968, 40(1):43-68.
116. Chow H.H., Cai Y., Alberts D.S., Hakim I., Dorr R., Shahi F., et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 2001, 10(1):53-58.
117. Chow H.H., Cai Y., Hakim I.A., Crowell J.A., Shahi F., Brooks C.A., et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003, 9(9):3312-3319.
118. Johnson J.J., Bailey H.H., Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 2010, 17(1):3-13.
119. Henning S.M., Aronson W., Niu Y., Conde F., Lee N.H., Seeram N.P., et al. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr 2006, 136(7):1839-1843.
120. Choan E., Segal R., Jonker D., Malone S., Reaume N., Eapen L., et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 2005, 23(2):108-113.
121. Jatoi A., Ellison N., Burch P.A., Sloan J.A., Dakhil S.R., Novotny P., et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97(6):1442-1446.
122. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66(2):1234-1240.
123. Nguyen M.M., Ahmann F.R., Nagle R.B., Hsu C.H., Tangrea J.A., Parnes H.L., et al. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 2012, 5(2):290-298.
124. McLarty J., Bigelow R.L., Smith M., Elmajian D., Ankem M., Cardelli J.A. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2009, 2(7):673-682.
125. Brausi M., Rizzi F., Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008, 54(2):472-473.
126. Chung L.Y., Cheung T.C., Kong S.K., Flung K.P., Choy Y.M., Chan Z.Y., et al. Induction of apoptosis by green tea catechins in human prostatew cancer DU124 cells. Life Sci 2001, 68(10):1207-1214.